Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. develops locally delivered, extended-release drug candidates using its proprietary Diffusphere technology, a polymer-based microsphere platform for targeted, controlled delivery. The company's news centers on clinical development of EP-104GI in eosinophilic esophagitis and EP-104IAR in knee osteoarthritis pain, including RESOLVE trial data, tissue-health and symptom measures, endoscopic and histologic scoring, and scientific conference presentations.
Recurring updates also cover financial results, clinical-supply and balance-sheet commentary, investor conference activity, and governance changes as Eupraxia advances its gastrointestinal and pain-focused development programs on Nasdaq and the TSX under EPRX.
Eupraxia Pharmaceuticals has announced the formation of a Clinical Advisory Board for its gastrointestinal program, specifically focusing on the EoE treatment. The board consists of renowned experts in the field who will guide the development of EP-104GI for eosinophilic esophagitis. The company aims to address the unmet medical needs of the EoE patient population with their proprietary DiffuSphere™ technology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.